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Summary Cardiovascular disease, such as atherosclerosis, is the main cause of mortality in
developed countries. Most atherosclerosis risk factors have been identiﬁed and are treated,
improving patient cardiovascular status and reducing mortality, but some remain unknown.Inﬂammation Periodontal disease is generally deﬁned as inﬂammatory disease initiated by accumulation of
dental bacterial plaque, leading to the destruction of tissues that support the teeth. Severe
forms have a high prevalence (15% of the population) and are associated with the presence
of virulent pathogens such as Porphyromonas gingivalis. Epidemiological studies have shown
that severe periodontal disease negatively inﬂuences cardiovascular status. The aim of this
Abbreviations: ACS, acute coronary syndrome; CHD, coronary heart disease; CRP, C-reactive protein; ICAM, intercellular adhesion molecule;
L, interleukin; LDL, low-density lipoprotein; MCP, monocyte chemotactic protein; M-CSF, macrophage colony-stimulating factor; MMP, matrix
etallopeptidase; PGE, prostaglandin E; TIMP, tissue inhibitor of metalloproteinases; TNF, tumour necrosis factor; VCAM, vascular cell
dhesion molecule.
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paper was to present a synthesis of the most recent biological data related to the link between
periodontal and cardiovascular disease. The potential biological mechanisms involved in these
two inﬂammatory diseases (bacteriological theory, inﬂammatory theory, immune theory) were
developed. According to the observed positive effects of periodontal treatment on systemic
conditions, the beneﬁt of a reinforced collaboration between dentists and cardiologists was
discussed, especially for patients at risk for cardiovascular disease.
© 2011 Elsevier Masson SAS. All rights reserved.
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Résumé Les maladies cardiovasculaires sont une cause majeure de mortalité dans les pays
développés. Malgré le fait que de nombreux facteurs de risque aient été mis en évidence et
que leurs prises en charge aient réduit l’impact de ces pathologies sur la mortalité, certains de
ces facteurs restent inconnus. Les maladies parodontales sont déﬁnies comme des pathologies
inﬂammatoires induites par certaines bactéries buccales ayant comme effet la destruction des
tissus de soutien dentaires. Les formes sévères de maladies parodontales ont une prévalence
importante (15 % de la population) et sont associées à la présence de certaines bactéries spé-
cialement virulentes tel Porphyromonas gingivalis. L’objectif de cet article est de présenter
une synthèse des données biologiques relatives au lien entre maladies parodontales et patholo-
gies cardiovasculaires. Les différents mécanismes biologiques impliqués (théorie bactérienne,
théorie inﬂammatoire, théorie immunitaire) seront traités et l’effet bénéﬁque des traitements
parodontaux sur certains paramètres biologiques seront discutés aﬁn de proposer auxcardio-
logues et aux dentistes des modalités de collaboration, notamment concernant les patients
présentant des facteurs de risque cardiovasculaires.
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Introduction
Cardiovascular disease, including atherosclerosis, is a major
public health concern. To ensure optimal treatment it is
important for cardiologists to be aware of all of the poten-
tial risk factors for these pathologies. For more than 20
years it has been proposed that periodontal disease could
inﬂuence the development of systemic disorders, increas-
ing cardiovascular disease and diabetes severity as well
as the rate of preterm birth [1—3]. Since then, many
clinical and experimental studies have investigated the
link between atherosclerosis and periodontal disease, with
variable conclusions [4]. A recent meta-analysis from ﬁve
prospective cohorts with coronary heart disease (CHD)
concluded that individuals with periodontitis had a 1.14-
time-higher risk of developing CHD than subjects without
periodontitis. The case-control and cross-sectional studies
included in this meta-analysis showed a greater association
(odds ratio 2.2) [5]. These data were conﬁrmed by Mustapha
et al. whose meta-analysis suggested a 1.75 average odds
ratio [6]. However, some studies consider that this relation-
ship is relatively weak and argue that additional controls
are needed to verify the relationship between these two
diseases [7]. Nevertheless, it is generally accepted that peri-
odontal disease may contribute to cardiovascular events or
stroke as shown by the recent consensus reports in dental
and cardiology journals [8—10].
Periodontal diseasePeriodontal disease is deﬁned as inﬂammatory and infec-
tious diseases of the gum and tooth-supporting tissues
caused by long-term accumulation of dental bioﬁlm and cal-
t
(s droits réservés.
ulus [11]. Periodontal disease can be classiﬁed as either
ingivitis, which is superﬁcial, reversible and relatively
armless, or as periodontitis, which is profound and irre-
ersible [11]. The main clinical signs of periodontitis are
ingival bleeding, gingival retraction, long appearance of
he teeth, tooth mobility, halitosis, abscess, periodontal
ocket formation, bone loss, tooth mobility and, in the most
evere cases, spontaneous tooth loss [12]. Periodontitis is
ore prevalent in men and the peak of incidence is at around
0 years of age. The disease progresses slowly for decades,
isplaying successive phases of activity that are more or
ess destructive [11]. Severe periodontitis affects almost
5—20% of the general population [11]. Periodontitis is char-
cterized by a strong inﬂammatory response and a rapid,
rofound and generalized destruction of periodontal tissues
ssociated with the presence of virulent bacteria such as
orphyromonas gingivalis, Aggregatibacter actinomycetem-
omitans and Treponema denticola [13]. In addition to a
otably impaired oral status, the negative inﬂuence of peri-
dontal disease on general health is revealed in cases of
evere periodontitis [14,15]. The diagnosis of periodonti-
is is generally based on the clinical symptoms described
bove, and many studies based on self-report have shown
hat patients were able to evaluate correctly but grossly
heir periodontal status [16]. However, the evaluation of
eriodontitis severity requires a speciﬁc clinical examina-
ion including periodontal pocket probing and radiological
xaminations performed by a periodontist or general dentist
Fig. 1). X-ray bone level measurements reﬂect the history
nd severity of the periodontitis, but do not necessarily cor-
elate with clinical parameters [11].Periodontal treatments consist of the mechanical (den-
al hygiene, scaling and root planning, surgery) and chemical
antiseptic, antibiotic) suppression of periodontal bioﬁlms.
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aigure 1. Clinical views of periodontitis. Major clinical signs are
hey efﬁciently decrease periodontal tissue inﬂammation
nd infection [17]. Furthermore, they improve some sys-
emic conditions (glycaemia, lipid metabolism, endothelial
unctions) [18]. However, a large part of the French popu-
ation is apparently not treated, especially patients at risk
or systemic disease [19].
ardiovascular disease
therosclerosis corresponds to the formation of atheroma-
ous plaques, which are responsible for CHD, acute coronary
yndromes (ACS) and ischaemic strokes, and represent
pproximately half of all cases of cardiovascular disease.
hey are the second highest cause of mortality in France.
n annual rate of 120 000 ACS and strokes leads to 40 000
nd 30 000 deaths, respectively. Men are more vulnerable
han women and the highest incidence is at approximately
5 years of age [20].
The formation of an atheromatous plaque or atheroscle-
osis is a slow phenomenon, more or less reversible initially
ue to the transport and oxidation of lipids from low-density
ipoprotein (LDL) on the arterial wall [21]. Classically, var-
ous anatomopathological forms of atheromatous plaque
ave been deﬁned (fatty streak, ﬁbrous cap) [22]. Recently,
he notion of stable or unstable/vulnerable plaque has been
roposed, to reﬂect the clinical consequences of atheroscle-
osis, such as ACS [23]. ACS is triggered by rupture of the
therosclerotic plaque, and reduced blood ﬂow leading to
n ischaemic lesion of the myocardium [22]. Plaque rup-
ure is still not considered as a natural evolution of the
therosclerosis process, but depends on speciﬁc pathogenic
athways [23]. The major risk factors for atherosclerosis
re dyslipidaemia, high blood pressure, tobacco smoking,
iabetes, socioeconomic stress, and advanced age, but
round 10% of patients with cardiovascular disease have
o conventional risk factors [24]. With the exception of
nstable angina, ACS and stroke, symptoms of atheroscle-
osis often remain subclinical, and its diagnosis is based
nitially on screening for the main risk factors. In order
o evaluate the severity of atherosclerosis, and in addi-
ion to new non-invasive techniques, considerable research
as been undertaken in the ﬁeld of biochemical mark-
rs that are characteristic of the status of atheromatous
laques [25]. Among these, inﬂammatory markers such as
-reactive protein (CRP) are routinely used to evaluate the
volution of atherosclerosis and cardiovascular risk. Indeed,
he inﬂammatory response to trapped lipids in arteries
lays an important (even predominant) role in the forma-
ion, and especially in the rupture, of the atherosclerotic
laque [23,26]. The experimental (mice ApoE−/−) and
a
o
t
ral inﬂammation (a), calculus (b) and gingival retraction (c).
he clinically observed (associated with diabetes, obesity,
utoimmune disease, infection) modiﬁcations of the inﬂam-
atory response encourage the formation of atherosclerotic
laques [27].
Similar to periodontal disease, the treatment of
therosclerosis is based mainly on the underlying causes,
ncluding improved regimens of lifestyle and diet, hypolip-
daemic drugs and corrective vascular surgery [26]. Since
980, a 20% decrease in ACS incidence has been observed
n France, due to the development of cardiovascular dis-
ase prevention and treatments and adherence to guidelines
28]. However, during the past 5 years, this decrease has
eclined, possibly due to the increasing incidence of dia-
etes and obesity. Furthermore, these data also highlight
he limits of the current atherosclerosis treatments and the
mportance of the investigation of new risk factors [26].
iological mechanisms
o explain the relationship between periodontal disease and
ardiovascular disease, and in particular atherosclerosis,
hree major biological theories have been proposed: the
acteriological theory, the inﬂammatory theory [27] and the
mmune theory [29].
he bacteriological theory
his theory refers to the concept of focal infection that
hows an association between oral ﬂora and systemic dis-
ase, especially endocarditis. It appears that some virulent
eriodontal pathogens such as P. gingivalis can dissemi-
ate from periodontal pockets to the general circulation
30] and are found in the atheromatous plaque and in
naffected vessels [31]. P. gingivalis produces numerous vir-
lence factors including gingipains, lipopolysaccharide or
mbriae [32] and may promote the development or evo-
ution of atheromatous plaque through different pathways.
hese bacteria can activate endothelial cells through Toll-
ike receptor 4 [33] and can induce apoptosis of endothelial
ells through different pathways or disrupt adhesion struc-
ures including integrin 1-cadherin complexes [34]. In vivo
tudies on apolipoprotein E-deﬁcient mice, which eventu-
lly develop atherosclerosis, show that oral or systemic
nfection with P. gingivalis accelerates the development of
therosclerosis [35]. It is important to notice that the
mounts of some periodontal pathogens, such as P. gingivalis
nd A. actinomycetemcomitans, vary depending on the form
f periodontitis [31]. The deeper the periodontal pockets,
he more important is the exchange surface between bacte-
ial bioﬁlms and blood circulation (15—20 cm2 in the most
Biological data linking periodontal disease and atherosclerosis
Figure 2. Bacterial theory: periodontal bacteria such as
P. gingivalis promote the development of atheromatous plaque via
virulence factors. The effects of bacteria on the atheromatous
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of oxidized LDL-cholesterol, facilitating their transforma-plaque are dependent on the presence of other cardiovascular risk
factors.
severe cases) [36]. Patients suffering from severe forms
of periodontitis have higher concentrations of P. gingivalis
and A. actinomycetemcomitans in periodontal pockets than
patients presenting moderate forms [37,38]. Many in vitro
[33], in vivo [35], and clinical [31] studies have suggested
that higher concentrations of these bacteria may increase
periodontal pathogen effects on endothelial cells and the
evolution of atheromatous plaques (Fig. 2).
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Figure 3. Process of atherogenesis and role of direct and indirect peri
Periodontal pathogens may directly and indirectly affect blood cells an
protein; Hsp: heat shock protein; IL-1b: interleukin-1b; MCP-1: monoc
factor; oxLDL: oxidized low-density lipoprotein; PGE2: prostaglandin E2
vascular cell adhesion molecule [39].355
he inﬂammatory theory
n periodontal disease, gingival cells produce proinﬂam-
atory factors such as tumour necrosis factor (TNF)-,
nterleukin (IL)1-, prostaglandin E2 (PGE)-2, matrix met-
lloproteinases and cathepsins [37,38]. Locally, these
ytokines induce the destruction of periodontal tissues and
ay also have systemic effects after entering the blood
tream. Stimulated endothelial cells in turn produce other
ediators of inﬂammation, including monocyte chemotactic
rotein (MCP)-1, macrophage colony-stimulating factor (M-
SF), intercellular adhesion molecule (ICAM), vascular cell
dhesion molecule (VCAM), P-selectin and E-selectin. These
ytokines accelerate the formation of atheromatous plaques
39]. The production of VCAM, P-selectin and E-selectin pro-
otes the transformation of leukocytes into macrophages.
CP-1 plays a role in the migration of monocytes, whereas
-CSF promotes their transformation into macrophages [39]
Fig. 3).
In vitro studies show that endothelial cells produce CRP
n response to infection with P. gingivalis [39]. CRP affects
acrophages in atherosclerotic plaques in the presenceion into foamy macrophages that are widely present in
therosclerotic plaques [40]. CRP has been demonstrated in
ivo to be localized at a high level in foamy macrophages
odontal factors.
d blood vessels, resulting in foam-cell formation. CRP: C-reactive
yte attractant protein-1; M-CSF: macrophage colony-stimulating
; ROI: rate of infection; TNF-a: tumour necrosis factor-a; VCAM:
356
Figure 4. Inﬂammatory theory: infection of epithelial cells by
periodontal bacteria promotes the production of proinﬂammatory
cytokines. These cytokines (TNF-, IL-1, PGE-2) enter the blood
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circulation and affect cells in atheromatous plaques, leading to the
evelopment of atherosclerosis in the presence of other risk factors.
n rabbits, which supports its involvement in the devel-
pment of atherosclerosis. The implications of CRP are
mportant. This protein is considered to be a key molecule
hat bridges inﬂammation and oxidative stress in endothelial
ells [41]. Therefore, it appears that cytokines synthesized
y epithelial cells during periodontal disease, as well as
hose produced by endothelial cells, amplify the inﬂamma-
ory process and promote the development of atheromatous
laques [39] (Fig. 4).
Clinically, it is important to notice that many patients
resent different cytokine proﬁles, depending on their form
f periodontal disease. Severe forms of periodontitis induce
ynthesis of more proinﬂammatory cytokines such as TNF-,
eading to a higher risk of general health complications com-
ared to patients with low or moderate forms of periodontal
isease [42].
he immune theory
wo distinct phenomena comprise the immune theory: the
rst concerns the level of inﬂammatory response, which
epends upon the individual concerned; and the second con-
erns the possible phenomenon of cross-reactivity.
In 1996, Beck et al. [43] proposed an initial hypothe-
is to explain the relationship between periodontal disease
nd atherosclerosis. The authors developed their the-
ry by taking into account individual differences in host
esponse against bacterial assault. This host response may
e abnormally large and cause the release of important
roinﬂammatory mediators such as PGE 2, IL1- or TNF-
y monocytes. This particular phenotype is called the mono-
ytic hyper-inﬂammatory phenotype and patients with this
henotype produce three to 10 times more proinﬂammatory
ediators in response to a stimulus by bacterial lipopolysac-
haride [43]. Patients with this phenotype are at risk of
eveloping periodontal disease because the cytokines pro-
uced by cells in contact with bacteria recruit inﬂammatory
a
[
b
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ells, degrade connective tissue and induce bone destruc-
ion; from the cardiovascular perspective, these patients are
t risk of cardiovascular disease due to the over-expression
f proinﬂammatory cytokines and dissemination through
lood ﬂow [43].
The second mechanism is an immunological phenomenon
f cross-reactivity due to molecular mimicry. This phe-
omenon describes the possibility that antibody responses
argeted against bacterial antigens can essentially func-
ion as autoimmune responses, due to the high degree
f homology between speciﬁc bacterial antigenic pep-
ides and mammalian proteins. It has been considered as
biologically plausible mechanism linking infection and
therosclerotic vascular disease [4]. During the atheroscle-
otic process, endothelial cells in response to stress,
uch as in hypertension, hypercholesterolemia or stimu-
ation by the lipopolysaccharide of P. gingivalis, produce
sp60 [29]. Antibodies against bacterial heat-shock pro-
eins, such as HSP60-related GroEL, may autoreact with
uman HSP60 expressed by activated endothelium, resulting
n cell destruction and therefore promoting the develop-
ent of atherosclerosis. Some studies revealed a high rate of
nti-Hsps 60, 65 and 70 in the arterial lesions [44]. This high
ate of anti-Hsp production can be explained by endothe-
ial injury, cell apoptosis or necrosis inside atheromatous
laques. Molecular mimicry contributes to maintaining the
utoimmune response and may have an important role in
he physiopathology of atherosclerosis, especially during the
arly stages of the disease [45] (Fig. 5).
ffects of periodontal treatment: the
ascular point of view
n general, periodontal treatment consists of professional
ygiene education, scaling and root planning with or without
ntibiotics, and may include surgical procedures for severe
orms [46]. Locally, periodontal therapy efﬁciently reduces
issue inﬂammation and the concentration of cytokines,
ncluding matrix metallopeptidase (MMP)-9, MMP-8, tissue
nhibitor of metalloproteinases (TIMP)-2 and myeloperoxi-
ase [47]. At the systemic level, a reduction in concentration
f inﬂammatory markers such as CRP, TNF-, E-selectin, IL-
8 and interferon- was also observed, notably in patients
ith cardiovascular disease [48]. Endothelial function was
lso improved 6 months after periodontal treatment, espe-
ially when antibiotics were used in conjunction with
echanical treatment [49]. Treatment in a single session
ppeared to give better results than treatment made by
uadrant, especially regarding the levels of IL-6 and throm-
omodulin [50]. Studies have observed beneﬁcial effects on
ystemic disease such as as diabetes or rheumatoid arthri-
is [18]. Elimination of bacterial factors and lower rates of
roinﬂammatory cytokines may improve the vascular status
46].
In response to the publication of recent studies, a
onsensus between the American Journal of Cardiology
nd the Journal of Periodontology was published in 2009
9]. For these authors, patients with periodontitis should
e informed that gum disease can increase the risk of
therosclerosis, and patients with periodontitis who had a
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Figure 5. Immune theory: the host’s immune system will react in response to the presence of bacteria. With the monocytic hyperinﬂam-
mation phenotype, the host reaction will lead to the production of cytokines, which are deleterious for host cells. Cross-reactivity between
of at
R
[anti-Hsp will induce destruction of host cells and the development
history of cardiovascular disease were prompted to attend
a medical examination. The most important part of this
consensus concerns patients suffering from both atheroscle-
rosis and periodontitis. For these patients, a reinforced
collaboration between cardiologists and periodontologists is
recommended to optimize periodontal care and reduce car-
diovascular disease risk. However, many aspects of the link
between cardiovascular and periodontal disease, as well as
the real impact of periodontal interventions on cardiovas-
cular events, remain to be clariﬁed or assessed [48]. Oral
infection and inﬂammation are detrimental to health and
having a healthy mouth is important for a healthy lifestyle;
periodontal treatment can improve both oral health and
cardiovascular outcomes [10].
Conclusion
Considering epidemiological and biological studies, it seems
important to consider periodontal disease as a risk fac-
tor for cardiovascular disease and atherosclerosis. Clinical
or in vitro studies show that periodontal monitoring and
treatment of patients with a risk of atherosclerosis or
cardiovascular disease may have positive effects. Collabo-
ration between cardiologists and periodontologists should
be encouraged, especially for patients with a history of
a cardiovascular event presenting with severe forms of
periodontitis. For these patients, but also for all patients
suffering from severe periodontitis, periodontal treatment
may be positive in terms of reducing the levels of inﬂamma-
tory cytokines and improving quality of life.Disclosure of interest
The authors declare that they have no conﬂicts of interest
concerning this article.
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